354 related articles for article (PubMed ID: 23697473)
1. Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients.
Watanabe T; Tanigawa T; Shiba M; Nadatani Y; Nagami Y; Sugimori S; Yamagami H; Watanabe K; Tominaga K; Fujiwara Y; Koike T; Arakawa T
Gut; 2014 Mar; 63(3):409-14. PubMed ID: 23697473
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage.
Watanabe T; Tanigawa T; Nadatani Y; Nagami Y; Sugimori S; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Fujiwara Y; Koike T; Arakawa T
Dig Liver Dis; 2013 May; 45(5):390-5. PubMed ID: 23333664
[TBL] [Abstract][Full Text] [Related]
3. Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users.
Muraki M; Fujiwara Y; Machida H; Okazaki H; Sogawa M; Yamagami H; Tanigawa T; Shiba M; Watanabe K; Tominaga K; Watanabe T; Arakawa T
Scand J Gastroenterol; 2014 Mar; 49(3):267-73. PubMed ID: 24417613
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs.
Sugimori S; Watanabe T; Tabuchi M; Kameda N; Machida H; Okazaki H; Tanigawa T; Yamagami H; Shiba M; Watanabe K; Tominaga K; Fujiwara Y; Oshitani N; Koike T; Higuchi K; Arakawa T
Digestion; 2008; 78(4):208-13. PubMed ID: 19142000
[TBL] [Abstract][Full Text] [Related]
5. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
6. Small intestinal injury in NSAID users suffering from rheumatoid arthritis or osteoarthritis.
Tachecí I; Bradna P; Douda T; Baštecká D; Kopáčová M; Rejchrt S; Lutonský M; Soukup T; Bureš J
Rheumatol Int; 2016 Nov; 36(11):1557-1561. PubMed ID: 27549792
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
8. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
Söderlin MK; Petersson IF; Geborek P
Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
[TBL] [Abstract][Full Text] [Related]
9. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
10. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.
Inoue T; Iijima H; Arimitsu J; Hagihara K; Kawai S; Shiraishi E; Hiyama S; Mukai A; Shinzaki S; Nishida T; Ogata A; Tsujii M; Takehara T
Digestion; 2014; 89(2):124-32. PubMed ID: 24526219
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
13. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy.
Fujimori S; Seo T; Gudis K; Ehara A; Kobayashi T; Mitsui K; Yonezawa M; Tanaka S; Tatsuguchi A; Sakamoto C
Gastrointest Endosc; 2009 Jun; 69(7):1339-46. PubMed ID: 19243767
[TBL] [Abstract][Full Text] [Related]
14. [Rheumatoid arthritis: current status of therapy].
El Bahri DM; Meddeb N; Sellami S
Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
[TBL] [Abstract][Full Text] [Related]
15. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
[TBL] [Abstract][Full Text] [Related]
17. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
18. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
Caporali R; Pallavicini FB; Filippini M; Gorla R; Marchesoni A; Favalli EG; Sarzi-Puttini P; Atzeni F; Montecucco C
Autoimmun Rev; 2009 Jan; 8(3):274-80. PubMed ID: 19017546
[TBL] [Abstract][Full Text] [Related]
19. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
Cairns AP; Taggart AJ
Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
